AMGNAmgen
Is it safe?
Strong, no red flags: clean books and quality strong.
Mixed, watch the balance sheet Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
High fundamental quality Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$4.1M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -25% · now 7% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AMGN take a bad year?
Amgen carries $43.3B of net debt at 3.07× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 3.07×
Net debt / EBITDA · 4.23× a year ago · the load is coming down
- Altman Z-score
- 1.73
Altman Z-score · distress zone, below 1.8
- Interest cover
- 4.28×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ2 2026
- $57.3B
- Cash and short-term investments
- $14.0B
- Net debt
- $43.3B
- EBITDA, trailing twelve months
- $14.1B
- Operating profit, trailing twelve months
- $11.4B
- Debt / equity
- 4.90×
- Total debt / EBITDA
- 4.06×
- Annualised volatilitytwo years of daily moves
- 28%
- Worst drawdown on file
- −25%
- Below its 52-week high
- 6.6%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, General
The closest names by size in the same industry